Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1681 1682 1699
This examiner grants 53% of resolved cases
Jehanne Souaya Sitton is an examiner in Art Unit 1634, part of Tech Center 1600. Across 679 resolved cases, the examiner maintains an allowance rate of 53.2%. This suggests that more than half of the applications result in a grant. The interview lift of 48.0% is very high, indicating that interviews are an exceptionally effective tool for advancing prosecution. The median days to allowance is 1324.
Practitioners should prioritize interviews to navigate the 1324-day timeline in Art Unit 1634. The 48.0% interview lift is one of the most significant metrics for this examiner. Across 679 resolved cases, the examiner has demonstrated that verbal advocacy is highly effective in Tech Center 1600. Strategy should focus on using the 48.0% lift to improve the 53.2% baseline grant probability. The 1324-day median pendency should be factored into all long-term planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17201469 | METHOD FOR DETECTING CYSTIC FIBROSIS | Final Rejection | QUEST DIAGNOSTICS INVESTMENTS LLC |
| 18724591 | LONG NON-CODING RNA BIOMARKER IN EXOSOMES FOR DIAGNOSING ATRIAL FIBRILLATION AND USE THEREOF | Non-Final OA | UIF (University Industry Foundation), Yonsei University |
| 18329972 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS | Final Rejection | Genentech, Inc. |
| 18471461 | IDENTIFYING DISEASE-CAUSING HUMAN DDX41 GENETIC VARIANTS | Final Rejection | Wisconsin Alumni Research Foundation |
| 18470759 | POLYCYSTIC KIDNEY DISEASE DIAGNOSIS AND TREATMENT BASED ON DETECTION OF PKD1/PKD2 VARIANTS | Final Rejection | Helix, Inc. |
| 17570315 | METHODS FOR DIAGNOSIS OF BACTERIAL AND VIRAL INFECTIONS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17596821 | Diagnostics and Treatments Based Upon Molecular Characterization of Colorectal Cancer | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 16644650 | Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) Variants And Uses Thereof | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18550008 | Methods of Identifying Active Lupus Nephritis Flare | Non-Final OA | Beth Israel Deaconess Medical Center, Inc. |
| 17596786 | OLIGONUCLEOTIDES FOR USE IN DETERMINING THE PRESENCE OF TRICHOMONAS VAGINALIS IN A SAMPLE | Non-Final OA | Gen-Probe Incorporated |
| 16832977 | GUT BACTERIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND METHODS THEREWITH IN DETECTING ILEAL FIBROSIS | Non-Final OA | Cedars-Sinai Medical Center |
| 18025365 | METHODS OF DETECTING AN INACTIVATING MUTATION OF PBRM1 IN MENINGIOMA | Non-Final OA | Foundation Medicine, Inc. |
| 17301187 | BIOMARKERS FOR ASSESSING IDIOPATHIC PULMONARY FIBROSIS | Final Rejection | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 16562861 | DIAGNOSTIC AND PROGNOSTIC LIQUID BIOPSY BIOMARKERS FOR ASTHMA | Non-Final OA | University of Sharjah |
| 17921936 | COMPOSITIONS AND METHODS FOR SEQUENCING USING POLYMER BRIDGES | Non-Final OA | Illumina, Inc. |
| 18537204 | RNA BIOMARKERS FOR HEREDITARY ANGIOEDEMA | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18248604 | DETERMINATION OF CELLULAR KINETICS AND BIODISTRIBUTION FOR CAR-T CELLS | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18556748 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17325839 | RAPID DIAGNOSTIC SYSTEM USING TARGETED ANTISENSE OLIGONUCLEOTIDE CAPPED PLASMONIC NANOPARTICLES | Non-Final OA | University of Maryland, Baltimore County |
| 16921287 | METHODS OF PREDICTING PREDISPOSITION TO OR RISK OF KIDNEY DISEASE | Non-Final OA | Wake Forest University Health Sciences |
| 17305480 | METHOD AND SYSTEM OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISEASE AND SEIZURES | Final Rejection | Morehouse School of Medicine |
| 16760522 | CANCER DETECTION, CLASSIFICATION, PROGNOSTICATION, THERAPY PREDICTION AND THERAPY MONITORING USING METHYLOME ANALYSIS | Final Rejection | SINAI HEALTH SYSTEM |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy